BMS-929075

Cat. No.:	HY-120634
CAS No.:	1217338-97-0
Molecular Formula:	$C_{31}H_{24}F_2N_4O_3$
Molecular Weight:	538.54
Target:	HCV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

BMS-929075 is a potent and orally active HCV NS5B replicase palm site allosteric inhibitor. BMS-929075 shows high oral bioavailability. BMS-929075 shows cytotoxicity[1].

In Vitro

BMS-929075 (0-60 μM) shows cytotoxicity with CC_{50} values of 60, >12.5, >50 μM for Huh-7, HepG2, primary human hepatocytes, respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BMS-929075 (compound 37) (2 mg/kg for i.v.; 6 mg/kg for p.o.) shows good pharmacokinetic parameters with oral bioavailability of 48% in rats[1].

Pharmacokinetic Parameters of BMS-929075 in Male Sprague-Dawley rats[1].

	IV			PO						
species	Cl (mL/min/kg)	IV $t_{1/2}$(hr)	V_{ss}(L/kg)	C_{max}(μM)	T_{max}(hr)	AUC (μM h)	C6 liver (μM)	C24 liver (μM)	C24 liver/plasma (μM)	F% (mL/min/kg)
rat	1.7	4.7	0.7	7.5	4	54.5	15.1	1.12	1.6	48

Rats, 2 mg/kg i.v.; 6 mg/kg p.o.[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Yeung KS, et al. Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. J Med Chem. 2017 May 25;60(10):4369-4385.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA